



(11) **EP 2 535 353 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography
Remarks

(51) Int Cl.:
C07K 16/24 (2006.01) **A61P 11/00** (2006.01)
A61P 19/02 (2006.01) **A61P 17/06** (2006.01)
A61P 35/02 (2006.01)

(48) Corrigendum issued on:
20.02.2013 Bulletin 2013/08

(43) Date of publication:
19.12.2012 Bulletin 2012/51

(21) Application number: **12181684.7**

(22) Date of filing: **12.11.2008**

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT
RO SE SI SK TR
Designated Extension States:
BA RS

(30) Priority: **13.11.2007 JP 2007294945**
14.02.2008 PCT/JP2008/052471

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
08848696.4 / 2 215 119

(71) Applicants:
• **Evec Inc.**
Sapporo 060-0042 (JP)
• **Boehringer Ingelheim International GmbH**
55216 Ingelheim am Rhein (DE)

(72) Inventors:
• **Takada, Kenzo**
Sapporo 060-0042 (JP)
• **Nakajima, Kantou**
Sapporo 060-0042 (JP)
• **Kistler, Barbara**
55216 Ingelheim am Rhein (DE)
• **Park, John**
55216 Ingelheim am Rhein (DE)

(74) Representative: **HOFFMANN EITLE**
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München (DE)

Remarks:

This application was filed on 24-08-2012 as a
divisional application to the application mentioned
under INID code 62.

(54) **Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same**

(57) Disclosed herein are anti-hGM-CSF mono-
clonal antibodies and antigen-binding fragments of such
antibodies, with improved neutralizing capacity to
hGM-CSF activity. Pharmaceutical compositions com-
prising such an antibody or antigen-binding fragment are
also provided. The present invention is useful for the
treatment of various diseases that are associated with
aberrant expression of hGM-CSF.




Fig. 8A